Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 9/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313056 | 0.86 | ELANE (0.46) | ELANECASP1CTRC | |
| SCHEMBL8312981 | 0.79 | ELANE (0.55) | ELANECASP3CTRC | |
| SCHEMBL13914028 | 0.75 | CTSK (0.63) | — | |
| SCHEMBL23835788 | 0.74 | NPC1 (0.58) | ELANECASP3CTRC | |
| SCHEMBL952097 | 0.72 | NPC1 (0.55) | ELANECASP3CASP1CTRC | |
| SCHEMBL487515 | 0.72 | CASP1 (0.48) | CASP3CASP1CASP7CASP9CASP6 | |
| SCHEMBL487514 | 0.72 | CASP1 (0.48) | CASP3CASP1CASP7CASP9CASP6 | |
| SCHEMBL14664262 | 0.72 | CASP1 (0.48) | CASP3CASP1CASP7CASP9CASP6 | |
| SCHEMBL1039441 | 0.72 | NPC1 (0.54) | ELANECASP3CASP1CTRC | |
| SCHEMBL1039440 | 0.72 | NPC1 (0.54) | ELANECASP3CASP1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | ELANE 242/4885CASP3 200/4885CASP1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.